Oxford BioMedica (OXB) Share Forecast & Price Target

Compare

85 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OXB Analyst Ratings

Strong Buy

3 Buy

1 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Oxford

BioMedica

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OXB Stock 12 Month Forecast

Average Price Target

617.70p

▲(8.37% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Oxford BioMedica in the last 3 months. The average price target is 617.70p with a high forecast of 931.08p and a low forecast of 400.47p. The average price target represents a 8.37% change from the last price of 570.00p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"195":"195p","932":"932p","379.25":"379.3p","563.5":"563.5p","747.75":"747.8p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":931.0817897148588,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">931.08p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":617.7024589,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">617.70p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":400.465285898864,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">400.47p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[195,379.25,563.5,747.75,932],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,569,596.8524453626815,624.7048907253629,652.5573360880444,680.4097814507257,708.2622268134072,736.1146721760887,763.9671175387701,791.8195629014516,819.672008264133,847.5244536268144,875.3768989894959,903.2293443521773,{"y":931.0817897148588,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,569,572.7463429923077,576.4926859846154,580.2390289769231,583.9853719692308,587.7317149615385,591.4780579538461,595.2244009461539,598.9707439384615,602.7170869307693,606.4634299230769,610.2097729153846,613.9561159076923,{"y":617.7024589,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,569,556.0357912229896,543.0715824459791,530.1073736689686,517.1431648919581,504.1789561149477,491.21474733793724,478.25053856092677,465.2863297839163,452.32212100690583,439.3579122298954,426.3937034528849,413.4294946758745,{"y":400.465285898864,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":196,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":287,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":372,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":381.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":405,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":295,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":328.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":464.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":569,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target931.08p

Average Price Target617.70p

Lowest Price Target400.47p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

James Vane

Jefferies

566p→687p

Buy

20.53%

Upside

Reiterated

09/03/25

Jefferies Sticks to Their Buy Rating for Oxford BioMedica (OXBDF)Jefferies analyst James Vane-Tempest raised the price target on Oxford Biomedica (OXB:LN) (OTC: OXBDF) to GBP6.87 (from GBP5.66) while maintaining a Buy rating.

Charles Weston

RBC Capital

800p→930p

Buy

63.16%

Upside

Reiterated

08/26/25

Oxford BioMedica (OXBDF) Gets a Buy from RBC Capital

Unknown Analyst

Peel Hunt

Not Ranked

Peel Hunt

451p

Buy

-20.88%

Downside

Reiterated

08/01/25

Peel Hunt Keeps Their Buy Rating on Oxford BioMedica (OXBDF)

James Gordon

J.P. Morgan

490p→400p

Hold

-29.82%

Downside

Reiterated

07/15/25

J.P. Morgan Remains a Hold on Oxford BioMedica (OXBDF)

James Orsborne

Stifel Nicolaus

500p

Buy

-12.28%

Downside

Reiterated

04/09/25

Oxford BioMedica: Promising Growth and Attractive Valuation Drive Buy Rating

Paul Cuddon

Deutsche Bank

250p→380p

Hold

-33.33%

Downside

Reiterated

09/24/24

Oxford Biomedica price target raised to 380 GBp from 250 GBp at Deutsche BankOxford Biomedica price target raised to 380 GBp from 250 GBp at Deutsche Bank

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

James Vane

Jefferies

566p→687p

Buy

20.53%

Upside

Reiterated

09/03/25

Charles Weston

RBC Capital

800p→930p

Buy

63.16%

Upside

Reiterated

08/26/25

Oxford BioMedica (OXBDF) Gets a Buy from RBC Capital

Unknown Analyst

Peel Hunt

Not Ranked

Peel Hunt

451p

Buy

-20.88%

Downside

Reiterated

08/01/25

Peel Hunt Keeps Their Buy Rating on Oxford BioMedica (OXBDF)

James Gordon

J.P. Morgan

490p→400p

Hold

-29.82%

Downside

Reiterated

07/15/25

J.P. Morgan Remains a Hold on Oxford BioMedica (OXBDF)

James Orsborne

Stifel Nicolaus

500p

Buy

-12.28%

Downside

Reiterated

04/09/25

Oxford BioMedica: Promising Growth and Attractive Valuation Drive Buy Rating

Paul Cuddon

Deutsche Bank

250p→380p

Hold

-33.33%

Downside

Reiterated

09/24/24

Oxford Biomedica price target raised to 380 GBp from 250 GBp at Deutsche BankOxford Biomedica price target raised to 380 GBp from 250 GBp at Deutsche Bank

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oxford BioMedica

1 Month

xxx

Success Rate

10/23 ratings generated profit

Average Return

+2.80%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 43.48% of your transactions generating a profit, with an average return of +2.80% per trade.

3 Months

xxx

Success Rate

13/23 ratings generated profit

Average Return

+3.88%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.52% of your transactions generating a profit, with an average return of +3.88% per trade.

1 Year

Charles WestonRBC Capital

Success Rate

10/23 ratings generated profit

Average Return

+7.33%

reiterated a buy rating 11 days ago

Copying Charles Weston's trades and holding each position for 1 Year would result in 43.48% of your transactions generating a profit, with an average return of +7.33% per trade.

2 Years

xxx

Success Rate

8/23 ratings generated profit

Average Return

-2.93%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 34.78% of your transactions generating a profit, with an average return of -2.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OXB Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OXB has received 5 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. OXB average Analyst price target in the past 3 months is 617.70.

Each month's total comprises the sum of three months' worth of ratings.

OXB Financial Forecast

OXB Earnings Forecast

Next quarter’s earnings estimate for OXB is -0.24p with a range of -0.28p to -0.20p. The previous quarter’s EPS was -0.08p. OXB beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year OXB has Preformed in-line its overall industry.

OXB Sales Forecast

Next quarter’s sales forecast for OXB is 72.70M with a range of 72.30M to 73.10M. The previous quarter’s sales results were 77.99M. OXB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.32% of the time in the same period. In the last calendar year OXB has Preformed in-line its overall industry.

OXB Stock Forecast FAQ

What is GB:OXB’s average 12-month price target, according to analysts?

Based on analyst ratings, Oxford BioMedica plc’s 12-month average price target is 617.70.

What is GB:OXB’s upside potential, based on the analysts’ average price target?

Oxford BioMedica plc has 8.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Oxford BioMedica plc a Buy, Sell or Hold?

Oxford BioMedica plc has a consensus rating of Strong Buy, which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.

What is Oxford BioMedica plc’s share price target?

The average share price target for Oxford BioMedica plc is 617.70. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 931.08p ,and the lowest forecast is 400.47p. The average share price target represents 8.37% Increase from the current price of 570p.

What do analysts say about Oxford BioMedica plc?

Oxford BioMedica plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Oxford BioMedica plc?

To buy shares of GB:OXB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Oxford BioMedica (OXB) Share Forecast & Price Target

OXB Analyst Ratings

OXB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Oxford BioMedica

OXB Analyst Recommendation Trends

OXB Financial Forecast

OXB Earnings Forecast

OXB Sales Forecast

OXB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts